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Abstract
Background: Cyclooxygenase-2 (COX-2) has recently been considered to promote lymphangiogenesis by up-
regulating vascular endothelial growth factor-C (VEGF-C) in breast and lung cancer. However, the impact of COX-2
on lymphangiogenesis of gastric cancer remains unclear. This study aims to test the expression of COX-2 and
VEGF-C in human gastric cancer, and to analyze the correlation with lymphatic vessel density (LVD),
clinicopathologic features and survival prognosis.
Methods: Using immunohistochemistry, COX-2, VEGF-C and level of LVD were analyzed in 56 R0-resected primary
gastric adenocarcinomas, while paracancerous normal mucosal tissues were also collected as control from 25
concurrent patients. The relationships among COX-2 and VEGF-C expression, LVD, and clinicopathologic parameters
were analyzed. The correlations of COX-2, VEGF-C and level of LVD with patient prognosis were also evaluated by
univariate tests and multivariate Cox regression.
Results: The expression rates of COX-2 and VEGF-C were 69.64% and 55.36%, respectively, in gastric carcinoma.
Peritumoral LVD was significantly higher than that in both normal and intratumoral tissue (P < 0.05). It was
significantly correlated with lymph node metastasis and invasion depth (P = 0.003, P = 0.05). VEGF-C was
significantly associated with peritumoral LVD (r = 0.308, P = 0.021). However, COX-2 was not correlated with VEGF-
C (r = 0.110, P = 0.419) or LVD (r = 0.042, P = 0.758). Univariate analysis showed that survival time was impaired by
higher COX-2 expression and higher peritumoral LVD. Multivariate survival analysis showed that age, COX-2
expression and peritumoral LVD were independent prognostic factors.
Conclusions: Although COX-2 expression was associated with survival time, it was not correlated with VEGF-C and
peritumoral LVD. Our data did not show that overexpression of COX-2 promotes tumor lymphangiogenesis
through an up-regulation of VEGF-C expression in gastric carcinoma. Age, COX-2 and peritumoral LVD were
independent prognostic factors for human gastric carcinoma.
Background
Gastric carcinoma is one of the most common digestive
malignancies in the world, especially in East and South-
east Asia, including China [1]. Regional lymph nodes are
the most common site of metastasis while lymph node
metastasis is a major prognostic factor in gastric carci-
nomas. Understanding the mechanisms of lymphatic
metastasis represents a crucial step and may result in a
new therapeutic target in the treatment of human
cancer. Lymphatic metastasis was previously believed to
occur through pre-existing lymphatics [2,3]. However,
recent studies have suggested that lymphangiogenesis,
the formation of new lymphatic vessels induced by
tumors, is directly correlated with the extent of lymph
node metastasis of solid tumors [4,5]. The degree of
lymphatic vessel density (LVD) can quantify tumor
lymphangiogenesis.
LVD of cancer tissue has been considered one of the
prognostic factors for survival outcome in various
cancers including gastric carcinoma [6,7]. Vascular
endothelial growth factor-C (VEGF-C) is the most
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important lymphangiogenic factor produced by tumor and
stromal cells. It has been found that VEGF-C is strongly
expressed and has become an important predictor of lym-
phangiogenesis and prognosis in numerous types of can-
cers, including gastric carcinoma [8-10]. VEGF-C can
promote lymphangiogenesis and lymph node metastasis of
tumors by activating its special receptor vascular endothe-
lial growth factor receptor-3 (VEGFR-3) [11,12].
Cyclooxygenase-2 (COX-2) is the rate-limiting enzyme
in prostaglandin synthesis and has been reported to be
overexpressed in various human cancers. During the
progression of a cancer, COX-2 takes part in many
pathophysiologic processes, including cell proliferation,
apoptosis, modulation of the immune system, and
angiogenesis [13-17]. The role of COX-2 in angiogenesis
of human cancers is well-documented and VEGF-A was
identified as a major downstream effector gene of COX-
2-induced angiogenesis in human cancer [18,19]. In con-
trast to the effect of COX-2 on angiogenesis, the effects
on lymphangiogenesis and lymphatic metastasis remain
poorly understood. Recently, some studies have found
that COX-2 expression is highly correlated with lymph
node metastasis [20,21]. Several lines of experimental evi-
dence have shown that COX-2 might stimulate VEGFR-3
to promote lymphangiogenesis by up-regulating VEGF-C
in breast and lung cancer cells [22,23].
However, the role of COX-2 in lymphangiogenesis of
gastric carcinoma remains unclear. Using immunohisto-
chemistry, our study aimed to detect the expression of
COX-2 and VEGF-C protein and the levels of lymphatic
vessel density (LVD) in human gastric cancer and ana-




Fifty-six patients with histologically proven gastric adeno-
carcinoma and who underwent radical gastrectomy at
West China Hospital, Sichuan University, China between
January 2001 and October 2002, were included in the
present investigation. In this investigation, paracancerous
normal mucosal tissues from 25 patients were collected
as a control. Patients undergoing neoadjuvant chemother-
apy and/or radiotherapy were excluded. TNM staging
was carried out according to the American Joint Com-
mittee on Cancer (AJCC) classification, and historical
grading was performed according to WHO criteria. Paraf-
fin-embedded, formalin-fixed surgical specimens were
prepared and collected for immunohistochemical staining.
Immunohistochemical staining
Specimens were immunostained with the standard
labeled streptavidin-biotin protocol. Briefly, after depar-
affinization and antigen retrieval, 4-μm tissue sections
were incubated with COX-2 antibodies (monoclonal
rabbit anti-human, 1:100, Goldenbridge Biotechnology
Co, Ltd, Beijing, China) and VEGF-C antibodies (poly-
clonal rabbit anti-human, 1:100, Goldenbridge Biotech-
nology Co., Ltd) at 37°C for 1 h then at 4°C overnight.
The sections were then incubated with biotinylated goat
anti-rabbit immunoglobulin G (1:200, Zymed Labora-
tories Inc, USA) and subsequently incubated with horse-
radish labeled streptavidin (1:200, Zymed Laboratories
Inc). 3,3’-Diaminobenzidine was used as a chromogen
and hematoxylin as a counterstain. For the staining of
lymphatic vessels, a rabbit anti-human D2-40 polyclonal
antibody (rabbit polyclonal, Dako Denmark A/S Co.,
Denmark) was used. The procedure for immunohisto-
chemical staining of D2-40 is similar to that of the
COX-2 staining at a dilution of 1:100.
Evaluation of immunohistochemical staining
The immunohistochemical score (IHS) based on the
German immunoreactive score was used for COX-2 and
VEGF-C immunohistochemical evaluation [24]. The IHS
is calculated by combining the quantity score (percen-
tage of positive stained cells) with the staining intensity
score. The quantity score ranges from 0 to 4, i.e. 0, no
immunostaining; 1, 1-10% of cells are stained; 2, 11-50%
are positive; 3, 51-80% are positive; and 4, ≥81% of cells
are positive. The staining intensity was scored as: 0
(negative), 1 (weak), 2 (moderate) and 3 (strong). Raw
data were converted to IHS by multiplying the quantity
score (0-4) by the staining intensity score (0-3). Theore-
tically, the scores can range from 0 to 12. An IHS of 9-
12 was considered a strong immunoreactivity; 5-8, mod-
erate; 1-4, weak; and 0, negative. In statistical analysis,
COX-2 and VEGF-C scores were placed in a high
expression group (strong and moderate immunoreactiv-
ity) and a low expression group (weak and negative
immunoreactivity). Immunoreactivity was scored by two
independent researchers.
LVD was detected by immunostaining for D2-40,
according to the criteria of Masakau et al. [25]. First,
areas with highly D2-40-positive vessels (hot spots) in
peritumoral, intratumoral and normal tissue were identi-
fied, by scanning the sections at low magnification
(×100); then the number of D2-40 positive vessels was
counted in five high-magnification fields (×400) for each
case. The mean value for the five fields was calculated
as the LVD for each tumor. To evaluate the impact of
LVD on prognosis, we divided the 56 cases into two
groups according to the mean LVD level.
Statistical analysis
Statistical analyses were performed with SPSS 11.5 soft-
ware (SPSS Inc, Chicago, USA). The correlations among
the expression of COX-2, VEGF-C, levels of LVD, and
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clinicopathologic characteristics were calculated by Stu-
dent’s t-test, chi-square correlation test and Spearman’s
coefficient of correlation as appropriate. The Kaplan-
Meier method was used to estimate survival as a func-
tion of time, and survival differences were analyzed with
the log-rank test. A multivariable test was performed to
determine the factor correlated with survival length by
Cox regression analysis. The statistical significance level
was defined as P < 0.05.
Results
Patient information
The 56 patients (35 males and 21 females) had a mean
age of 56.2 (range 27-74) years. Twenty-six of the cases
displayed weight loss, and 17 presented anemia with
hemoglobin (HGB) < 90 g/l. Histological examination
showed that 4 displayed well differentiated adenocarci-
noma, 18 moderate and 34 poor. According to the sixth
AJCC TNM classification, 16 patients were in stage I, 18
in stage II, 19 in stage III, and 3 in stage IV. Of the 56
patients, 39 (69.6%) had lymph node metastasis. Up to
2008, there were 32 patients in total that had died.
COX-2, VEGF-C and D2-40 expression in gastric carcinoma
Positive expression of COX-2 protein and VEGF-C
showed as a yellow or brownish yellow stain in the cyto-
plasm of carcinoma cells (Figures 1 and 2). The expres-
sion rates of COX-2 and VEGF-C were 69.64% (39/56)
and 55.36% (31/56), respectively, in gastric carcinoma.
However, normal tissue showed no immunoreactivity
for COX-2 and VEGF-C.
Immunoreactivity of D2-40 proteins was found in
the cytoplasm and cellular membrane of lymphatic
endothelial cells. The distribution of D2-40-positive cells
was frequently located in peritumoral tissue (hot spot)
(Figure 3A). The means of LVD in peritumoral, intratu-
moral and normal tissue of the 56 gastric carcinomas
were 9.24 ± 4.51, 2.88 ± 2.04, 2.69 ± 1.78, respectively.
The LVD in peritumoral, intratumoral (Figure 3B) and
normal tissue (Figure 3C) was significantly different by
variance analysis of randomized block design. When
compared to each other by least significant difference
(LSD) test, there was a significant difference between
the peritumoral LVD and both the intratumoural LVD
and the LVD of normal tissue. There was no significant
difference between the intratumoral LVD and the LVD
of normal tissue. When the mean peritumoral LVD of
9.24 was chosen as the cut-off point for discrimination
of the 56 patients, 32 patients were categorized in the
low LVD group and 24 in the high LVD group.
Correlation between COX-2, VEGF-C and LVD and
clinicopathologic characteristics
The correlation of COX-2, VEGF-C and peritumoral
LVD with clinicopathologic factors in gastric carcinoma
is shown in Table 1. There was no significant correla-
tion between COX-2 expression and any clinicopatholo-
gic characteristics, including gender, age, lymph node
metastasis, histological differentiation, invasion depth
and TNM stage (P > 0.05, chi-square test). Similarly,
VEGF-C expression was not correlated with any clinico-
pathologic characteristics (P > 0.05, chi-square test).
The peritumoral LVD was significantly correlated with
lymph node metastasis and invasion depth. It was higher
in the lymph node metastasis group (10.37 ± 4.61) than
in the no lymph node metastasis group (6.64 ± 3.01)
Figure 1 Immunohistochemical staining of Cox-2 in the gastric
carcinoma: the positive expression of COX-2 protein was
stained as yellow or brownish yellow in the cytoplasm of
carcinoma cells (LsAB, ×400).
Figure 2 Immunohistochemical staining of VEGF-C in the
gastric carcinoma: the positive expression of VEGF-C protein
was stained as yellow or brownish yellow in the cytoplasm of
carcinoma cells (LsAB, ×400).
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(P = 0.003, t-test) and was higher in the T3,T4 group
(10.80 ± 5.24) than in the T1,T2 group (8.37 ± 3.85) (P =
0.05, t-test). No significant correlation was observed with
the rest of the clinicopathologic parameters (P > 0.05,
t-test).
Correlation between COX-2, VEGF-C and LVD
The expression of COX-2 was not significantly correlated
with VEGF-C expression (r = 0.110, P > 0.419) and peri-
tumoral LVD (r = 0.042, P > 0.05). Peritumoral LVD in
VEGF-C positive expression gastric carcinoma was 10.45 ±
5.11, which was significantly higher than that in VEGF-C
negative expression gastric carcinoma (7.73 ± 3.09, P =
0.023). Peritumoral LVD was significantly associated with
VEGF-C (r = 0.308, P = 0.021) (Table 2).
Survival analyses
Univariate prognostic analyses
Within a total follow-up period of 60 months, 32 of
the 56 assessable cases had died. The 5-year overall
survival (OS) for all patients was 42.9%. Analysis of
the impact of COX-2 status is shown in Figure 4. Six
cases had died in the COX-2 low expression group
and the 5-year OS was 64.7% whereas 26 cases had
died in the COX-2 high expression group and the 5-
year OS was 33.3%. Patients with high COX-2 expres-
sion tended to have poorer prognosis than patients
with low COX-2 expression (P = 0.026, log-rank test).
The 5-year OS of patients with low and high VEGF-C
expression was 48% and 38.71%, respectively. Kaplan-
Meier curves of overall survival stratified by VEGF-C
status are shown in Figure 5. The survival time of
patients in different expression groups showed no sig-
nificant difference (P > 0.05, log-rank test). Analysis
of the impact of LVD status is shown in Figure 6. The
5-year OS of patients with low and high LVD was
59.4% and 20.8%, respectively. Patients with high peri-
tumoral LVD tended to have poorer prognosis than
patients with low peritumoral LVD (P = 0.001, log-
rank test).
Figure 3 Immunohistochemical staining of D2-40: Immunoreactivity of D2-40 proteins was found in the cytoplasm and cellular
membrane of lymphatic endothelial cells. A. Detection of lymphatic vessels in the peritumoral tissue of gastric carcinoma was highlighted by
immunostaining against D2-40 (LsAB,×200). B. Immunohistochemical staining of D2-40 in the intratumoral tissue of gastric carcinoma (LsAB,
×200). C. Immunohistochemical staining of D2-40 the normal gastric mucosal tissue (LsAB, ×200).
Table 1 Correlation between COX-2, VEGF-C, peritumoral LVD and clinicopathologic factors in gastric carcinoma
Parameters N COX-2 expression VEGF-C expression LVD
Low High P value Low High P value Mean ± SD P value
Histological grading
Low 34 11 23 0.916 16 18 0.703 9.03 ± 4.37 0.721
Moderate 18 5 13 8 10 9.88 ± 5.15
Well 4 1 3 1 3 8.14 ± 2.69
Depth of invasion
T1+T2 36 12 24 0.516 17 19 0.602 8.37 ± 3.85 0.052
T3+T4 20 5 15 8 12 10.80 ± 5.24
Lymph node metastasis
No 17 5 12 0.919 10 7 0.159 6.64 ± 3.01 0.003
Yes 39 12 27 15 24 10.37 ± 4.61
TNM stage
I+ II 34 11 23 0.686 18 16 0.12 8.40 ± 3.95 0.084
III+IV 22 6 16 7 15 10.53 ± 5.08
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Multivariate analysis and Cox’s proportional hazard model
In Cox regression for OS including patients’ age, gender,
lymph node metastasis, histological differentiation, inva-
sion depth, stage, COX-2 expression, VEGF-C expres-
sion, and peritumoral LVD, only age (P = 0.015, RR =
2.891, 95% confidence interval, 1.228-6.805), COX-2
expression (P = 0.021, RR = 3.244, 95% confidence
interval, 1.192-8.828) and peritumoral LVD (P = 0.001,
RR = 4.292, 95% confidence interval, 1.778-10.360)
remained as independent prognostic factors.
Discussion
The occurrence of lymphangiogenesis can be detected
using several lymphatic vessel-specific markers. Pre-
viously, the lack of specific lymphatic molecular markers
for lymphatic endothelium was the main obstacle to
studying tumor lymphangiogenesis. D2-40, a novel
monoclonal antibody, is a selective marker of lymphatic
endothelium. It is specifically expressed on lymphatic
but not vascular endothelial cells, compared with tradi-
tional lymphatic endothelium markers [26-28]. In this
study, as shown in the results, D2-40 is only expressed
in lymphatics and is negative in blood vessels and the
distribution of D2-40 positive cells is exclusively in peri-
tumoral tissue.
In the present study, the LVD of peritumoral tissue
was significantly higher than that in both normal and
intratumoral tissue. Peritumoral LVD is significantly
related to the depth of invasion, lymph node metastasis
and prognosis. Patients with high peritumoral LVD tend
to have a poorer prognosis than patients with low peri-
tumoral LVD. The role of intratumoral versus peritu-
moral lymphatics for lymph node metastasis remains
controversial. Many studies have found an increased
LVD in peritumoral tissue and peritumoral lymphangio-
genesis is significantly correlated with lymph node
metastasis and prognosis in human solid cancer
[2,29-33]. However, the presence or absence of intratu-
moral lymphangiogenesis and the functional significance
Table 2 Correlation between COX-2 and VEGF-C,
peritumoral LVD
COX-2 peritumoral LVD
VEGF-C Coefficient 0.110 0.308
P value 0.419 0.021
COX-2 Coefficient 0.042
P value 0.758
Figure 4 Kaplan-Meier overall survival curves for 56 patients
with gastric carcinoma patients with COX-2 positive expression
had a significantly worse OS compared with those with COX-2
negative expression.
Figure 5 Kaplan-Meier overall survival curves for 56 patients
with gastric carcinoma: patients with VEGF-C expression had
no association with survival time of gastric carcinoma.
Figure 6 Kaplan-Meier overall survival curves for 56 patients
with gastric carcinoma: patients with high peritumoral LVD
had a significantly worse OS compared with those with low
peritumoral LVD.
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of intratumoral lymphatic vessels remain controversial
[3]. Several studies have found lymphatics only in peri-
tumoral tissue [34,35]. Padera et al. have reported that
tumor cells are not able to metastasis by intratumoral
lymphatic vessels [2], but other studies have demon-
strated that the presence of intratumoral lymphangio-
genesis and intratumoral LVD are correlated with lymph
node metastasis and prognosis in several tumors [36-38].
Among the reported transduction systems in lym-
phangiogenesis in humans, the VEGF-C/VEGFR-3 axis
is the main system [12,39]. VEGF-C is vital for the lym-
phangiogenic process supported by transgenic and gene
deletion animal models [40-42]. It has been shown to be
expressed highly and has a negative influence on prog-
nosis and a positive correlation with lymph node metas-
tasis including gastric carcinoma [8-10,43,44]. However,
Arinaga et al. found that there was no significant corre-
lation between VEGF-C and lymph node metastasis in
non-small cell lung carcinoma [45]. In a univariate ana-
lysis, Möbius et al. reported that tumoral VEGF-C
expression of adenocarcinoma of the esophagus was not
a significant prognostic factor [46]. Our results showed
that primary gastric carcinoma tissue elevated the
expression of VEGF-C. However, there was no signifi-
cant association between the expression rate of VEGF-C
and clinicopathologic parameters. Probably, these discre-
pancies were influenced by intratumoral heterogeneity
and the population size. But, in this study, there was a
positive correlation between the expression of VEGF-C
and peritumoral LVD.
The overexpression of COX-2 has been detected in
several types of human cancer including colon, lung, sto-
mach, pancreas and breast cancer and is usually asso-
ciated with poor prognostic outcome. Cox-2 mRNA and
protein were first found to be expressed in human gastric
carcinoma by Ristimaki et al. in 1997 [47]. Previous stu-
dies show conflicting prognostic significance of COX-2
in gastric carcinoma. Johanna et al. found that there was
a significant association between COX-2 expression and
lymph node metastasis and invasive depth, and high
COX-2 is an independent prognostic factor in gastric
cancer [48]. However, contrary to the above results, some
studies have shown that there was no association
between COX-2 expression and prognosis [49]. Lim also
found that there was no correlation between clinico-
pathological characteristics of gastric cancer patients and
intensity of COX-2 protein expression [50]. In our study,
we also found that COX-2 protein was expressed in cases
of gastric carcinoma, but we did not find a significant
association between COX-2 expression and clinicopatho-
logical characteristics. In this study, from univariate and
multivariate analyses, we found a significant association
between COX-2 expression and a reduced survival of
patients with gastric cancer. These discrepancies are
likely influenced by differences in study size, COX-2
detection methods, and criteria for COX-2 overexpres-
sion. These findings warrant larger studies with multi-
variate analysis to clarify the association of COX-2 with
clinicopathological characteristics and poor prognosis in
patients with gastric cancer.
In contrast to the effect of COX-2 on angiogenesis,
the effect on lymphangiogenesis and lymphatic metasta-
sis remains poorly understood. Recent studies suggest
that COX-2 may play a role in tumor lymphangiogen-
esis through an up-regulation of VEGF-C expression.
VEGF-C is the most important lymphangiogenic factor
produced by tumor and stromal cells. Su et al. [23]
found that lung adenocarcinoma cell lines transfected
with Cox-2 gene or exposed to prostaglandin E2 caused
a significant elevation of VEGF-C mRNA and protein.
The authors suggested that Cox-2 up-regulated VEGF-
C by an EP1 prostaglandin receptor and human epider-
mal growth factor receptor HER-2/Neu-dependent
pathway. In addition, immunohistochemical staining of
59 lung adenocarcinoma specimens reflected a close
association between COX-2 and VEGF-C. Kyzas et al.
[51] found that there was a significant correlation
between COX-2 expression and VEGF-C expression,
and lymph node metastasis in head and neck cancer.
Timoshenko et al. [22] found that VEGF-C expression
and secretion could be inhibited by down-regulation of
COX-2 with COX-2 siRNA in human breast cancer.
Several reports have also revealed that there was a sig-
nificant association between COX-2 expression and
lymph node metastasis, and COX-2 expression was cor-
related with VEGF-C expression in gastric carcinoma
[20,52]. These results indicated that a lymphangiogenic
pathway, in which COX-2 up-regulated VEGF-C
expression, might exist in human carcinoma. However,
contrary to the above results, some studies have shown
that there was no association between COX-2 expres-
sion and lymph node metastasis in many types of
cancer, including gastric carcinoma [50,53-57]. Further-
more, some studies found that there was no association
between COX-2 expression and VEGF-C expression or
COX-2 and VEGF-C mRNA levels in several types of
cancer [57-59]. In our study, we did not find correla-
tions between COX-2 and VEGF-C, or COX-2 and
LVD. Though COX-2 expression was associated with
survival time, COX-2 was not correlated with VEGF-C
or LVD. Our data did not show that overexpression of
COX-2 promotes tumor lymphangiogenesis through an
up-regulation of VEGF-C expression in gastric carci-
noma. This difference is based upon the smaller num-
ber of specimens examined (mostly n < 100), a biased
selection of patients, different scoring systems, or differ-
ent antibodies used. In addition, most studies were
retrospective.
Gou et al. Journal of Experimental & Clinical Cancer Research 2011, 30:14
http://www.jeccr.com/content/30/1/14
Page 6 of 8
Conclusions
The overexpression of VEGF-C and COX-2 has been
found in gastric carcinoma tissues. Age, COX-2 and
peritumoral LVD were independent prognostic factors
for human gastric carcinoma. Although COX-2 expres-
sion was associated with survival time, it was not corre-
lated with VEGF-C or peritumoral LVD. Our data did
not show that overexpression of COX-2 promotes
tumor lymphangiogenesis through an up-regulation of
VEGF-C expression in gastric carcinoma. These findings
warrant further larger studies to clarify the association
between COX-2 and lymphangiogenesis in gastric
cancer.
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